Multaq and Trelegy ellipta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Multaq (dronedarone hydrochloride) and Trelegy ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate). Common drug interactions include pain among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Multaq and Trelegy ellipta. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Multaq?

Multaq has active ingredients of dronedarone hydrochloride. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 11,053 Multaq users. Check the latest studies of Multaq.

What is Trelegy ellipta?

Trelegy ellipta has active ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 28,101 Trelegy ellipta users. Check the latest studies of Trelegy ellipta.

On Jul, 16, 2026

16 people who take Multaq and Trelegy ellipta together, and have interactions are studied.

Multaq and Trelegy ellipta drug interactions.

What are the common drug interactions of Multaq and Trelegy Ellipta, by gender? *:

female:

Pain
Arthralgia (joint pain)
Asthma
Back pain
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Fatigue (feeling of tiredness)
Headache (pain in head)
Infusion related reaction
Lower respiratory tract infection
Nasopharyngitis (inflammation of the nasopharynx)

male:

Death
Arthralgia (joint pain)
Wheezing (a high-pitched whistling sound made while you breath)
Back pain
Cough
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Hypoacusis (loss of hearing)
Productive cough
Squamous cell carcinoma of skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin)

What are the common drug interactions of Multaq and Trelegy Ellipta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Chronic kidney disease
Death
Urinary tract infection
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Nephrogenic anaemia (anaemia due to kidney disease)
Renal failure (kidney dysfunction)
Biliary colic
Dyspnoea (difficult or laboured respiration)
Haemoglobin decreased

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 4 people, 25.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 18.75%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 12.50%
Multiple Myeloma (cancer of the plasma cells): 2 people, 12.50%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 6.25%
Asthma: 1 person, 6.25%
Back Pain: 1 person, 6.25%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 1 person, 6.25%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 6.25%
Cough: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Multaq and Trelegy ellipta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously